News | Prostate Cancer | November 19, 2018

Higher Pretreatment Immune Inflammatory Levels Linked to Lower Disease-Free Survival in Prostate Cancer

Validation study from NRG-RTOG 0521 also suggests no association between elevated C-reactive protein and disease-free survival

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer

November 19, 2018 — Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment interleukin 10 (IL-10) were linked to lower rates of disease-free survival (DFS). The data suggests there is no association between an elevated level of C-reactive protein (CRP) and DFS. Results were presented at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Oct. 21-24 in San Antonio, Texas.

The initial study, NRG-RTOG 0521, indicated that elevated CRP levels, a marker of inflammation, were directly associated with shorter biochemical failure-free survival after radiotherapy for patients with high-risk prostate cancer. During this study, serum samples were collected from 202 participants and banked for future biomarker validation. Researchers measured multiple serum immuno-inflammatory cytokines in addition to CRP levels. The primary objective for the validation study was to determine the association between CRP levels and DFS from time of patient randomization, and additional objectives included the correlation of cytokine levels with DFS and toxicity events due to radiotherapy.

“Although CRP levels did not correlate with DFS, the association of higher baseline levels of IL-10 with poorer outcome supports the claim that there may be an interaction between host pretreatment immune inflammatory state and the outcomes for the patient following radiotherapy treatment. I believe that future investigation into anti-inflammatory medical intervention for patients with prostate cancer in association to radiotherapy would be worthwhile,” stated William A. Hall, M.D., an assistant professor of radiation oncology at the Medical College of Wisconsin and lead author of this abstract.

Serum immune-inflammatory cytokines that were studied included:

  • Monocyte chemotactic protein-1 (MCP-1);
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF);
  • Interferon gamma (IFN-γ);
  • IL-1b;
  • IL-2;
  • IL-4;
  • IL5;
  • IL-6;
  • IL-8;
  • IL-10;
  • IL-12;
  • IL-13;
  • IL-17A;
  • IL-23; and
  • Tumor necrosis factor (TNFα).

In addition to the association between IL-10 and DFS, IL-12 and IL-13 were also associated with grade 2 or higher cystitis, or inflammation of the bladder.

For more information: www.astro.org

Related Content

High-dose Radiation Effective for Men Whose Prostate Cancer Has Spread
News | Prostate Cancer | September 23, 2019
A randomized clinical trial of targeted, high-dose radiation for men with oligometastatic prostate cancer has shown the...
First Patients Treated With Machine Learning-generated Plans from RayStation 8B
News | Treatment Planning | September 23, 2019
The first-ever patient radiation therapy treatments generated with machine learning in the RayStation treatment...
An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart. #ASTRO19 #ASTRO2019 #ASTRO

An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart.

Feature | ASTRO | September 23, 2019
August 29, 2019 — The American Society for Radiation Oncology (ASTRO) announced th
Videos | Radiation Oncology | September 20, 2019
Anne Hubbard, MBA, director of health policy for ASTRO, explains the details and purpose of the proposed Radiation On
Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial
News | Breast Density | September 20, 2019
Densitas Inc. announced it has won a procurement of its densitas densityai software for deployment in up to 24 breast...
Videos | Radiation Therapy | September 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with...
Aktina Showcases New Radiotherapy Patient Immobilization Solutions at ASTRO 2019
News | Patient Positioning Radiation Therapy | September 20, 2019
Aktina Medical introduced several new products at the 2019 American Society for Radiation Oncology (ASTRO) annual...
Varian Announces Multi-room Configuration for ProBeam 360 Proton Therapy System
News | Proton Therapy | September 20, 2019
Varian announced its ProBeam 360° proton therapy system is now available in a multi-room configuration. The ProBeam 360...
Screening Mammography Could Benefit Men at High Risk of Breast Cancer
News | Mammography | September 18, 2019
Selective mammography screening can provide potentially lifesaving early detection of breast cancer in men who are at...
Anne Hubbard, MBA, director of health policy for the American Society for Radiation Oncology

Anne Hubbard, MBA, director of health policy for the American Society for Radiation Oncology (ASTRO), explains the details of the proposed radiation oncology alternative payment model (APM), and issues ASTRO has raised with the model, at the 2019 ASTRO annual meeting in Chicago.

News | Radiation Oncology | September 18, 2019
During its annual meeting in September, the American Society for Radiation Oncology (ASTRO) issued a response to the...